![]() |
Boehringer Ingelheim Initiates Phase III Clinical Trial With Afatinib In Advanced Bre
Boehringer Ingelheim Pharmaceuticals, Inc. announced the initiation of a phase III clinical trial in the United States to investigate one of its oncology pipeline compounds, afatinib* (BIBW 2992), for the treatment of patients with advanced (metastatic) breast cancer...
More... |
| All times are GMT -7. The time now is 04:04 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2026, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021